Skip to main content
. 2024 Apr 18;16(4):e58536. doi: 10.7759/cureus.58536

Figure 1. Participant flow diagram.

Figure 1

Group I: Standard antidiabetic medications + SGLT2 inhibitor; Group II: Standard antidiabetic medications